The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

Summary

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.

Conditions

• Ischemic Heart Disease (IHD)
• Cardiac Magnetic Resonance Imaging
• Myocardial Blood Flow

Interventions

DIAGNOSTIC_TEST

Quantitative Myocardial Blood Flow Evaluation

The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.

DIAGNOSTIC_TEST

Qualitative Myocardial Blood Flow Evaluation

The perfusion sequence will not produce additional quantitative perfusion maps.

DRUG

Gadavist

Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).

DRUG

Vasodilator

All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).

DIAGNOSTIC_TEST

Blood draw for the laboratory assessment

A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.

Sponsors & Collaborators

• Brigham and Women's Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

35 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-06-27

Primary Completion

2029-01-31

Completion

2029-03-31

Countries

• United States

Study Locations